ABSTRACT

Leishmaniasis is an important complex of protozoal vector-borne diseases that affect both humans and animals. Leishmania donovani (L. donovani) complex consist of member such as L. infantum, L. donovaniand L. chagasi and has considered as an etiological agent for fatal visceral leishmaniasis disease. Recently, data shows that anti-parasitic agents for overcoming the limitations of present-day leishmaniasis chemotherapy toxicity. Indirubin is the active component of Danggui Longhui Wan (a traditional Chinese medicine formulation). Indirubin has been used in herbal medicine since ancient times, with various biological applications. Indirubin is a non- toxic, highly promising natural antioxidants compound having a wide spectrum of biological function. Although some research has been done on the possible medicinal uses, no studies for drug- development have been carried out as yet. Although the crude extract has numerous medicinal uses, clinical application can be also made only after extensive research on its bioactivity, mechanism of action, pharmacotherapeutics and toxicity studies. The leishmanicidal activity progressively lessened with decreasing concentration of drug. In MTT assay, O.D. is decreasing with the increasing concentration of indirubin and 50% growth inhibitory concentration was 30 ?M of indirubin. About 50% of parasites were killed at 30 ?M (indirubin). In-vivo study indirubin against of L.donovani showed maximum reduction (50%) in spleen weight of mice. According to the present data, Indirubin showed goodanti- leishmanial activity against promastigotes of L. donovanistarin AG83. It is expected the indirubin may find application as a novel drug in the near future to control leishmaniasis. Keyword: Leishmaniasis, Indirubin, Leishmania donovani, L. macropodum, L. enriettii

https://ijbpas.com/pdf/2019/March/MS_IJBPAS_2019_46641.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2019/8.3.4664